CRNA Stock Overview
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Circio Holding ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr2.70 |
52 Week High | kr23.97 |
52 Week Low | kr2.41 |
Beta | 1.98 |
1 Month Change | -55.00% |
3 Month Change | -58.02% |
1 Year Change | -85.25% |
3 Year Change | -98.90% |
5 Year Change | -98.59% |
Change since IPO | -99.63% |
Recent News & Updates
Recent updates
Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price
Aug 24Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?
Jul 08Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Oct 27Is Targovax (OB:TRVX) A Risky Investment?
Jul 05Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now
Mar 10Is Targovax (OB:TRVX) Using Debt In A Risky Way?
Feb 20The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares
Dec 05Shareholder Returns
CRNA | NO Biotechs | NO Market | |
---|---|---|---|
7D | -6.9% | -1.7% | 1.7% |
1Y | -85.2% | -67.2% | 4.1% |
Return vs Industry: CRNA underperformed the Norwegian Biotechs industry which returned -66.4% over the past year.
Return vs Market: CRNA underperformed the Norwegian Market which returned 4.6% over the past year.
Price Volatility
CRNA volatility | |
---|---|
CRNA Average Weekly Movement | 16.1% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 5.2% |
10% most volatile stocks in NO Market | 10.3% |
10% least volatile stocks in NO Market | 3.0% |
Stable Share Price: CRNA's share price has been volatile over the past 3 months.
Volatility Over Time: CRNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 17 | Erik Wiklund | www.circio.com |
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system.
Circio Holding ASA Fundamentals Summary
CRNA fundamental statistics | |
---|---|
Market cap | kr20.56m |
Earnings (TTM) | -kr110.74m |
Revenue (TTM) | kr123.00k |
167.1x
P/S Ratio-0.2x
P/E RatioIs CRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRNA income statement (TTM) | |
---|---|
Revenue | kr123.00k |
Cost of Revenue | kr0 |
Gross Profit | kr123.00k |
Other Expenses | kr110.86m |
Earnings | -kr110.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -14.54 |
Gross Margin | 100.00% |
Net Profit Margin | -90,029.27% |
Debt/Equity Ratio | -114.9% |
How did CRNA perform over the long term?
See historical performance and comparison